Target therapy for hepatocellular carcinoma: is sorafenib for everybody?

J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / adverse effects
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / pathology
  • Disease-Free Survival
  • Humans
  • Liver Cirrhosis / pathology*
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Niacinamide / analogs & derivatives
  • Patient Selection
  • Phenylurea Compounds
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*
  • Risk Assessment
  • Severity of Illness Index
  • Sorafenib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Niacinamide
  • Sorafenib